Skip to content

Author

B. Zurawski

1 paper indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Sep 2026

34 Belzutifan Plus Lenvatinib Versus Cabozantinib in Post–PD-(L)1 Renal Cell Carcinoma: Health-Related Quality-of-Life Outcomes in the Phase 3 LITESPARK-011 Study

Abstract Background Belzutifan plus lenvatinib significantly improved progression-free survival and objective response rate versus cabozantinib, and had manageable safety, in participants with advanced renal cell carcinoma (RCC) that progressed on or after anti-programmed cell death protein 1 and anti-programmed cell d...

M. Schmidinger, Daniel Y. C. Heng, Ray McDermott et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.